Jagsonpal Pharmaceuticals Ltd
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Jagsonpal appoints Amrut Medhekar as COO effective September 4, 2025; veteran pharma executive with ~30 years' experience.
-
Announcement under Regulation 30 (LODR)-Change in Management
2d - Amrut Medhekar appointed COO effective September 04, 2025; 28-year pharma executive, ex-Akums Drugs CEO; MBA, IIM certificate included.
-
Letter To Shareholders For Annual Report Web-Link And Path
2 Sep - 46th AGM on 24 Sep 2025 15:30 IST via VC; Annual Report 2024-25 available at https://www.jagsonpal.com/annual-report/
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Sep - Newspaper Publication of Notice of 46th Annual General Meeting and E- voting information
-
Business Responsibility and Sustainability Reporting (BRSR)
1 Sep - Submitted BRSR FY2024-25; disclosed ₹5,09,79,206 customs penalty, appeal lodged May 27, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Jul 2025Transcript PPT REC
-
Jul 2025TranscriptNotesPPT
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Oct 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands